Drug:WD-890

Phase 3

ZZhejiang Wenda Pharma Technology LTD.

Drug:WD-890 is one of 3 therapeutic programs targeting Moderate-to-severe Plaque Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Moderate-to-Severe Plaque PsoriasisRecruiting

Moderate-to-Severe Plaque PsoriasisPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Moderate-to-Severe Plaque Psoriasis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

4 2

Drug:WD-890

ZZhejiang Wenda Pharma Technology LTD.

Phase 3

1 3

HS-20118

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Moderate-to-Severe Plaque Psoriasis

NCT07672561

Clinical

Trials by Indication[1]

Moderate-to-severe Plaque Psoriasis1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Recruiting·ZZhejiang Wenda Pharma Technology LTD.·Phase 3·NCT07672561·375 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug:WD-890. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug:WD-890. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhejiang Wenda Pharma Technology LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: ZZhejiang Wenda Pharma Technology LTD.

Drug:WD-890

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Moderate-to-severe Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News